Myths That Make Early CDMO Engagement Look Like A Risk

By Artur Padzik, Technology Manager, 3PBIOVIAN

Many AAV gene therapy programs fail not because the biology is flawed, but because manufacturing risk is addressed too late. Despite strong clinical data, regulators routinely issue Complete Response Letters driven by CMC deficiencies, scaling failures, and inadequate analytical strategies. This article examines persistent myths that delay early CDMO engagement—and quietly undermine otherwise promising programs.

From the misconception that lab-scale success directly translates to GMP, to the belief that manufacturing cost is merely an operational concern, each myth contributes to late-stage surprises with severe regulatory and commercial consequences. The article draws on regulatory data, industry case studies, and CDMO platform experience to show how early, phase-appropriate collaboration transforms manufacturing risk into actionable insight.

Rather than premature industrialization, early engagement enables smarter process choices, stronger comparability positioning, defensible potency strategies, and more credible CMC narratives. In a landscape where most delays are manufacturing-driven, early CDMO partnership may be the most overlooked success factor in gene therapy development.